Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor

被引：0
|
作者：
Kato, Jun-Ya [1 ]
Korenaga, Shigeru [2 ]
Iwakura, Masaru [1 ]
机构：
[1] Synthetic Research Department, ASKA Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Kanagawa, Fujisawa,251-8555, Japan
[2] Drug Discovery Department, ASKA Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Kanagawa, Fujisawa,251-8555, Japan
来源：
SSRN | 2022年
关键词：
Compilation and indexing terms; Copyright 2024 Elsevier Inc;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Amino acids - Enzymes
引用
收藏
相关论文
共 50 条
  • [41] Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
    Gerstenberger, Brian S.
    Ambler, Catherine
    Arnold, Eric P.
    Banker, Mary-Ellen
    Brown, Matthew F.
    Clark, James D.
    Dermenci, Alpay
    Dowty, Martin E.
    Fensome, Andrew
    Fish, Susan
    Hayward, Matthew M.
    Hegen, Martin
    Hollingshead, Brett D.
    Knafels, John D.
    Lin, David W.
    Lin, Tsung H.
    Owen, Dafydd R.
    Saiah, Eddine
    Sharma, Raman
    Vajdos, Felix F.
    Xing, Li
    Yang, Xiaojing
    Yang, Xin
    Wright, Stephen W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (22) : 13561 - 13577
  • [42] JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Nogueira, Miguel
    Puig, Luis
    Torres, Tiago
    DRUGS, 2020, 80 (04) : 341 - 352
  • [43] A TYK2 Gene Mutation c.2395G>A Leads to TYK2 Deficiency: A Case Report and Literature Review
    Wu, Peilin
    Chen, Suqing
    Wu, Bin
    Chen, Junhong
    Lv, Ge
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [44] Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
    Mease, Philip J.
    Deodhar, Atul A.
    van der Heijde, Desiree
    Behrens, Frank
    Kivitz, Alan J.
    Neal, Jeffrey
    Kim, Jonghyeon
    Singhal, Shalabh
    Nowak, Miroslawa
    Banerjee, Subhashis
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 815 - 822
  • [45] TYK2 Promoter Variant and Diabetes Mellitus in the Japanese
    Nagafuchi, Seiho
    Kamada-Hibio, Yumi
    Hirakawa, Kanako
    Tsutsu, Nobutaka
    Minami, Masae
    Okada, Akira
    Kai, Katsuya
    Teshima, Miho
    Moroishi, Arisa
    Murakami, Yoshikazu
    Umeno, Yoshikazu
    Yokogawa, Yasushi
    Kogawa, Kazuhiko
    Izumi, Kenichi
    Anzai, Keizo
    Iwakiri, Ryuichi
    Hamaguchi, Kazuyuki
    Sasaki, Nobuhiro
    Nohara, Sakae
    Yoshida, Eiko
    Harada, Mine
    Akashi, Koichi
    Yanase, Toshihiko
    Ono, Junko
    Okeda, Toshimitsu
    Fujimoto, Ryoji
    Ihara, Kenji
    Hara, Toshiro
    Kikuchi, Yohei
    Iwase, Masanori
    Kitazono, Takanari
    Kojima, Fumiko
    Kono, Suminori
    Kurisaki, Hironori
    Kondo, Shiori
    Katsuta, Hitoshi
    EBIOMEDICINE, 2015, 2 (07): : 744 - 749
  • [46] Discovery of the TYK2 selective inhibitor PF-6826647 for the treatment of Crohn's disease, and other autoimmune conditions
    Gerstenberger, Brian
    Arnold, Eric
    Banker, Mary Ellen
    Brown, Matthew
    Clark, James
    Dermenci, Alpay
    Dowty, Martin
    Fensome, Andrew
    Hayward, Matthew
    Hegen, Martin
    Hollingshead, Brett
    Knafels, John
    Lin, David
    Lin, Tsung
    Owen, Dafydd
    Saiah, Eddine
    Sharma, Raman
    Vajdos, Felix
    Vincent, Fabien
    Wright, Stephen
    Xing, Li
    Yang, Xiaojing
    Yang, Xin
    Zhang, Liying
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [47] Functional analyses of three human TYK2 variants
    Ragimbeau, Josiane
    Gakovic, Milica
    Eloranta, Maija L.
    Pellegrini, Sandra
    CYTOKINE, 2008, 43 (03) : 241 - 241
  • [48] The TYK2 gene is associated with susceptibility to multiple sclerosis
    Mero, I. L.
    Lorentzen, A. R.
    Ban, M.
    Smestad, C.
    Celius, E. G.
    Aarseth, J. H.
    Myhr, K. M.
    Link, J.
    Hillert, J.
    Olsson, T.
    Kockum, I.
    Masterman, T.
    Oturai, A.
    Sondergaard, H. B.
    Sellebjerg, F.
    Saarela, J.
    Kemppinen, A.
    Spurkland, A.
    Lie, B. A.
    Harbo, H.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S186 - S186
  • [49] Response:: The hyper IgE and mutations syndrome in TYK2
    Minegishi, Yoshiyuki
    Saito, Masako
    Karasuyama, Hajime
    IMMUNITY, 2007, 26 (05) : 536 - 536
  • [50] TYK2 inhibition: changing the treatment landscape for psoriasis?
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (03) : 185 - 187
12345